HB3180 103RD GENERAL ASSEMBLY

LRB103 29935 RLC 56350 b

103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024
HB3180

Introduced 2/17/2023, by Rep. Tom Weber

SYNOPSIS AS INTRODUCED:

720 ILCS 570/210

from Ch. 56 1/2, par. 1210

Amends the Illinois Controlled Substances Act. Adds Clonazolam as a Schedule IV controlled substance.

A BILL FOR

AN ACT concerning criminal law.

Be it enacted by the People of the State of Illinois, represented in the General Assembly:

Section 5. The Illinois Controlled Substances Act is amended by changing Section 210 as follows:

(720 ILCS 570/210) (from Ch. 56 1/2, par. 1210)

Sec. 210. (a) The controlled substances listed in this Section are included in Schedule IV.

(b) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing limited quantities of any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, as set forth below:

(1) Not more than 1 milligram of difenoxin (DEA Drug Code No. 9618) and not less than 25 micrograms of atropine sulfate per dosage unit.

(2) Dextropropoxyphene (Alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane).

(c) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a depressant effect on the central nervous system:

(1) Alprazolam;

(2) Barbital;

(2.1) Bromazepam;

(2.2) Camazepam;

(2.3) Carisoprodol;

(3) Chloral Betaine;

(4) Chloral Hydrate;

(5) Chlordiazepoxide;

(5.1) Clobazam;

(6) Clonazepam;

(6.1) Clonazolam;

(7) Clorazepate;

(7.1) Clotiazepam;

(7.2) Cloxazolam;

(7.3) Delorazepam;

(8) Diazepam;

(8.05) Dichloralphenazone;

(8.1) Estazolam;

(9) Ethchlorvynol;

(10) Ethinamate;

(10.1) Ethyl loflazepate;

(10.2) Fludiazepam;

(10.3) Flunitrazepam;

(11) Flurazepam;

(11.1) Fospropofol;

(12) Halazepam;

(12.1) Haloxazolam;

(12.2) Ketazolam;

(12.3) Loprazolam;

(13) Lorazepam;

(13.1) Lormetazepam;

(14) Mebutamate;

(14.1) Medazepam;

(15) Meprobamate;

(16) Methohexital;

(17) Methylphenobarbital (Mephobarbital);

(17.1) Midazolam;

(17.2) Nimetazepam;

(17.3) Nitrazepam;

(17.4) Nordiazepam;

(18) Oxazepam;

(18.1) Oxazolam;

(19) Paraldehyde;

(20) Petrichloral;

(21) Phenobarbital;

(21.1) Pinazepam;

(22) Prazepam;

(22.1) Quazepam;

(23) Temazepam;

(23.1) Tetrazepam;

(23.2) Tramadol;

(24) Triazolam;

(24.5) Zaleplon;

(25) Zolpidem;

(26) Zopiclone.

(d) Any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers and salts of isomers is possible:

(1) Fenfluramine.

(e) Unless specifically excepted or unless listed in another schedule any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Cathine ((+)-norpseudoephedrine);

(1.1) Diethylpropion;

(1.2) Fencamfamin;

(1.3) Fenproporex;

(2) Mazindol;

(2.1) Mefenorex;

(3) Phentermine;

(4) Pemoline (including organometallic complexes and chelates thereof);

(5) Pipradrol;

(6) SPA ((-)-1-dimethylamino-1, 2-diphenylethane);

(7) Modafinil;

(8) Sibutramine.

(f) Other Substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substance, including its salts:

(1) Butorphanol (including its optical isomers).

(g) The Department may except by rule any compound, mixture, or preparation containing any depressant substance listed in subsection (b) from the application of all or any part of this Act if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a depressant effect on the central nervous system.

(h) Except as otherwise provided in Section 216, any material, compound, mixture, or preparation that contains any quantity of the following substance having a stimulant effect on the central nervous system, including its salts, enantiomers (optical isomers) and salts of enantiomers (optical isomers):

(1) Ephedrine, its salts, optical isomers and salts of optical isomers.

(Source: P.A. 97-334, eff. 1-1-12.)